TY  - JOUR
T1  - A new era in stroke prevention for atrial fibrillation: Comment on “current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation
AU  - Singer DE, MD, Go AS, MD
Y1  - 2012/04/23
N1  - 10.1001/archinternmed.2012.897
JO  - Archives of Internal Medicine
SP  - 631
EP  - 633
VL  - 172
IS  - 8
N2  - 
Atrial fibrillation, the most common significant cardiac arrhythmia, raises the risk of ischemic stroke 5-fold. Dose-adjusted warfarin therapy reduces this risk by two-thirds.2 However, warfarin therapy is burdensome and risky, and its effect varies as a result of food and drug interactions and genetic differences.3 The safe management of warfarin therapy demands frequent international normalized ratio (INR) testing and dose adjustment as well as ongoing patient education regarding common hazards. The risks of ischemic stroke and intracranial hemorrhage are minimized at INR values of 1.8 to 3.5.4 Beyond this range, the risks increase steeply.

SN  - 0003-9926
M3  - doi: 10.1001/archinternmed.2012.897
UR  - http://dx.doi.org/10.1001/archinternmed.2012.897
ER  -